CR11612A - Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina - Google Patents

Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina

Info

Publication number
CR11612A
CR11612A CR11612A CR11612A CR11612A CR 11612 A CR11612 A CR 11612A CR 11612 A CR11612 A CR 11612A CR 11612 A CR11612 A CR 11612A CR 11612 A CR11612 A CR 11612A
Authority
CR
Costa Rica
Prior art keywords
vlp
influenza virus
influenza
hemaglutinine
produced
Prior art date
Application number
CR11612A
Other languages
English (en)
Inventor
Marc-Andre D'aqust
Manon Couture
Frederic Ors
Sonia Trepanier
Pierre-Olivier Lavoie
Michele Dargis
Louis-Philippe Vezina
Nathalie Landry
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002615372A external-priority patent/CA2615372A1/en
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of CR11612A publication Critical patent/CR11612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Software Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Se proporciona un metodo para sintetizar particulas tipo virus de influenza (VLP) dentro de una planta o una porcion de una planta. El metodo involucra expresion de HA de influenza en plantas y la purificacion por cromatografia por exclusion de tamano. La invencion tambien se dirige hacia una VLP que comprende la proteina HA de influenza y lipidos de plantas. La invencion tambien se dirige a un acido nucleico que codifica HA de influenza asi como vectores. Las VLP pueden usarse para formular vacunas de la influenza, o pueden usarse para enriquecer las vacunas existentes.
CR11612A 2007-11-27 2010-07-29 Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina CR11612A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99060307P 2007-11-27 2007-11-27
US1327207P 2007-12-12 2007-12-12
CA002615372A CA2615372A1 (en) 2007-07-13 2008-01-21 Influenza virus-like particles (vlps) comprising hemagglutinin
US2277508P 2008-01-22 2008-01-22
PCT/CA2008/001281 WO2009009876A1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
PCT/CA2009/000032 WO2009076778A1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin

Publications (1)

Publication Number Publication Date
CR11612A true CR11612A (es) 2010-09-13

Family

ID=40795157

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11612A CR11612A (es) 2007-11-27 2010-07-29 Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina

Country Status (18)

Country Link
US (4) US20100310604A1 (es)
EP (2) EP2238253B1 (es)
JP (4) JP2011509661A (es)
KR (1) KR20100120157A (es)
CN (2) CN101978066A (es)
AU (1) AU2009202819B2 (es)
CA (1) CA2707235C (es)
CR (1) CR11612A (es)
DK (1) DK2610345T3 (es)
ES (1) ES2554703T3 (es)
IL (1) IL206967A (es)
IS (1) IS2982B (es)
MA (1) MA32439B1 (es)
MX (1) MX2010007962A (es)
NZ (1) NZ587108A (es)
PT (1) PT2610345E (es)
WO (1) WO2009076778A1 (es)
ZA (1) ZA201005917B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) * 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
MX370690B (es) 2008-07-18 2019-12-19 Medicago Inc Epitopo de inmunizacion de nuevo virus de la influenza.
RU2559527C2 (ru) 2008-11-28 2015-08-10 Мериал Лимитед Рекомбинантная вакцина от птичьего гриппа и её применение
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
HRP20180706T1 (hr) * 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
PH12012500565B1 (en) 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
IN2012DN06277A (es) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
CN103260643A (zh) 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
WO2012041503A1 (en) 2010-09-30 2012-04-05 Franvax S.R.L. Generation of virosome particles
CN103282501A (zh) * 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CN103476399A (zh) * 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
WO2012145759A2 (en) * 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Methods of protein production and compositions thereof
JP5846624B2 (ja) * 2011-05-30 2016-01-20 公益財団法人ヒューマンサイエンス振興財団 Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット
US20140227322A1 (en) * 2011-06-13 2014-08-14 Medicago Inc. Rabies virus like particle production in plants
IN2014CN02114A (es) 2011-09-20 2015-05-29 Sinai School Medicine
GB201116416D0 (en) * 2011-09-23 2011-11-02 Isis Innovation Composition
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
AU2012315421C1 (en) 2011-09-30 2019-12-05 Aramis Biotechnologies Inc. Increasing virus-like particle yield in plants
CA2872803C (en) * 2012-05-11 2016-10-11 Medicago Inc. Rotavirus-like particle production in plants
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
CN112592389A (zh) * 2013-03-28 2021-04-02 莫迪卡戈公司 植物中流感样病毒颗粒的产生
CA2936350C (en) 2014-01-10 2023-01-31 Medicago Inc. Cpmv enhancer elements
AU2015234595B2 (en) 2014-03-27 2021-03-25 Medicago Inc. Modified CPMV enhancer elements
CA2954759C (en) 2014-07-11 2021-09-14 Medicago Inc. Modifying protein production in plants
CA2974438A1 (en) 2015-01-23 2016-07-28 Medicago Inc. Rotavirus-like particle production in plants
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
US10584148B2 (en) * 2015-06-02 2020-03-10 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
KR20180088629A (ko) 2015-07-02 2018-08-06 메디카고 인코포레이티드 자스몬산 경로 활성화제
US10844097B2 (en) 2016-06-02 2020-11-24 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
FR3054547B1 (fr) * 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
US11191825B2 (en) * 2016-09-16 2021-12-07 Vaccitech, Inc. Compositions and methods for vaccination against influenza
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
GB201708866D0 (en) 2017-06-02 2017-07-19 Univ Cape Town Expression of chaperone proteins in planta for increased expression of heterologous polypeptides of interest
CN107058377A (zh) * 2017-06-16 2017-08-18 深圳惠升生物科技有限公司 植物作为宿主在表达中东呼吸综合征的疫苗中的应用
EP3682012A1 (en) * 2017-09-11 2020-07-22 R. J. Reynolds Tobacco Company Methods and compositions for increasing expression of genes of interest in a plant by co-expression with p21
CA3093592A1 (en) 2018-03-14 2019-09-19 Medicago Inc. Plant expression enhancer
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
SG11202012349QA (en) 2018-06-27 2021-01-28 Medicago Inc Influenza virus hemagglutinin mutants
WO2020035619A1 (en) 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Rna-based biocontrol methods to protect plants against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
JP7512546B2 (ja) 2019-03-14 2024-07-09 アラミス バイオテクノロジーズ インコーポレイテッド 内因性植物発現エンハンサー
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
EP4077684A1 (en) * 2019-12-18 2022-10-26 Genethon Production of recombinant viral vectors from plant hairy roots
BR112022021208A8 (pt) * 2020-04-22 2023-02-23 Medicago Inc Supraestrutura compreendendo hemaglutinina de influenza modificada com interação reduzida com ácido siálico
EP4141121A4 (en) * 2020-04-22 2024-07-10 POSTECH Research and Business Development Foundation RECOMBINANT HEMAGGLUTININ PROTEIN DERIVED FROM TRIMER-FORMING INFLUENZA VIRUS SURFACE PROTEIN AND USE THEREOF
CN111888390B (zh) * 2020-08-27 2021-12-14 广州白云山星群(药业)股份有限公司 夏桑菊提取物在抑制人类冠状病毒中的应用
CN120249318A (zh) * 2025-04-01 2025-07-04 华南农业大学 mRNA及其mRNA-LNP疫苗与制备方法、用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
JPS62501263A (ja) 1984-11-29 1987-05-21 スクリツプス　クリニツク　アンド　リサ−チ　フアウンデ−シヨン 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体
JPS61265086A (ja) 1985-05-21 1986-11-22 Mitsui Toatsu Chem Inc プロトプラストの培養法
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
DE69213804T2 (de) * 1991-03-28 1997-03-27 Rooperol Na Nv Zusammensetzungen von Phytosterolen mit Phytosterolinen als Immunmodulatoren
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
AU6504796A (en) 1995-07-20 1997-02-18 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
WO2000009725A2 (en) 1998-08-11 2000-02-24 Biosource Technologies, Inc. Method for recovering proteins from the interstitial fluid of plant tissues
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
CA2365592C (en) 1999-04-29 2011-11-15 Zeneca Limited Herbicide resistant plants comprising epsps
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
WO2002074795A2 (en) 2001-01-18 2002-09-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2003219745B8 (en) * 2002-02-13 2008-10-09 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
KR101070518B1 (ko) * 2002-03-19 2011-10-05 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서의 ｇｎｔⅲ 발현
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
NZ542933A (en) * 2003-05-05 2009-08-28 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
ATE473271T1 (de) * 2003-05-05 2010-07-15 Thompson Boyce Plant Res Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7226781B1 (en) 2003-07-24 2007-06-05 Belyaev Alexander S Chaperone expression genomes
WO2006016380A2 (en) 2004-08-13 2006-02-16 Council Of Scientific And Industrial Research A chimeric g protein based rabies vaccine
US9155483B2 (en) 2004-12-03 2015-10-13 The Invention Science Fund I, Llc Vision modification with reflected image
ATE541938T1 (de) 2005-04-29 2012-02-15 Univ Cape Town Expression viraler proteine in pflanzen
CN100410378C (zh) * 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 编码禽流感血凝素的基因及其植物表达载体和应用
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
EP1945250A4 (en) 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE AGAINST INFLUENZA
JP5714799B2 (ja) 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
SG169996A1 (en) 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
US7993655B2 (en) 2006-04-21 2011-08-09 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2029755A1 (en) 2006-05-22 2009-03-04 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
WO2008148104A1 (en) 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
DK2155880T3 (en) 2007-06-15 2016-12-05 Medicago Inc Modification of glycoproteinproduktion i plants
KR100964462B1 (ko) * 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
US20110059130A1 (en) 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
JP2011508034A (ja) 2007-12-28 2011-03-10 ユニリーバー・ナームローゼ・ベンノートシヤープ 茶から香気成分を回収する方法
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
MX370690B (es) 2008-07-18 2019-12-19 Medicago Inc Epitopo de inmunizacion de nuevo virus de la influenza.
JP5785080B2 (ja) 2008-08-27 2015-09-24 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 植物におけるワクチン及びモノクローナル抗体治療薬の高レベル迅速生産のためのｄｎａレプリコン系
WO2010042551A2 (en) 2008-10-06 2010-04-15 Genvault Corporation Methods for providing cellular lysates from cell wall-containing samples
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
HRP20180706T1 (hr) * 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
PH12012500565B1 (en) 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
CA2789945A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CN103282501A (zh) * 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
BR112013011194B1 (pt) 2010-11-05 2020-12-22 Novavax, Inc partícula micelar, composição farmacêutica compreendendo a mesma, uso de uma partícula micelar e método de preparação de uma micela
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
CN108611793B (zh) 2018-05-18 2020-11-20 北京化工大学 一种高强度静电纺丝聚丙烯腈基纳米碳纤维毡的制备方法

Also Published As

Publication number Publication date
JP2014097076A (ja) 2014-05-29
AU2009202819A1 (en) 2009-06-25
MX2010007962A (es) 2010-11-10
US9458470B2 (en) 2016-10-04
HK1186207A1 (en) 2014-03-07
JP5990207B2 (ja) 2016-09-07
WO2009076778A8 (en) 2009-08-27
IS2982B (is) 2017-09-15
JP2016032477A (ja) 2016-03-10
JP6215363B2 (ja) 2017-10-18
IL206967A (en) 2014-11-30
CA2707235A1 (en) 2009-06-25
JP2011509661A (ja) 2011-03-31
MA32439B1 (fr) 2011-07-03
WO2009076778A1 (en) 2009-06-25
CN101978066A (zh) 2011-02-16
NZ587108A (en) 2013-04-26
EP2610345B1 (en) 2015-08-19
JP2016052331A (ja) 2016-04-14
ES2554703T3 (es) 2015-12-22
EP2238253A4 (en) 2011-04-06
US10190132B2 (en) 2019-01-29
US20100310604A1 (en) 2010-12-09
EP2238253B1 (en) 2012-09-12
BRPI0906960A8 (pt) 2015-09-29
PT2610345E (pt) 2016-01-11
US20170088848A1 (en) 2017-03-30
IL206967A0 (en) 2010-12-30
CA2707235C (en) 2013-11-19
IS8919A (is) 2010-08-04
CN103122354A (zh) 2013-05-29
ZA201005917B (en) 2013-10-30
US20190177739A1 (en) 2019-06-13
BRPI0906960A2 (pt) 2015-07-14
EP2610345A1 (en) 2013-07-03
AU2009202819B2 (en) 2014-08-28
KR20100120157A (ko) 2010-11-12
US20130142826A1 (en) 2013-06-06
EP2238253A1 (en) 2010-10-13
CN103122354B (zh) 2018-03-23
US11434497B2 (en) 2022-09-06
DK2610345T3 (en) 2015-12-07

Similar Documents

Publication Publication Date Title
CR11612A (es) Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
CO6960508A2 (es) Composiciones y métodos para incrementar la resistencia a nematodos en plantas
AR084726A1 (es) Metodos para aumentar el rendimiento y la produccion de productos quimicos finos en plantas
PE20150645A1 (es) Proteinas de fusion de interleuquina 10 y usos de las mismas
MX373717B (es) Composiciones concentradas para la limpieza personal y metodos.
MX2010002753A (es) Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas.
CL2008002727A1 (es) Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos
PY1562426A (es) Moléculas de ácido nucléico de subunidad copi coatomer alfa que confieren una resistencia a plagas de coleópteros y hemípteros
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
CL2015000642A1 (es) Molécula de ácido nucleico que codifica un polipéptido de alfavirus salmonoide (sav) o virus de la enfermedad del páncreas del salmón (spdv); polipéptido codificado; método para inducir respuesta inmune contra alfavirus de salmón; y vacuna.
MX2013012329A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
AR067748A1 (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
BR112015023738A2 (pt) vacinas de nucleoproteina influenza
AR081155A1 (es) Plantas que tienen modificados rasgos relacionados con el rendimiento y un metodo para producirlas
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
AR079036A1 (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producir plantas con expresion de o-fut, bps, siz1, bsip-s o tipo spa 15 modulada
DK201370530A (en) Salmonid alphavirus vaccine
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
AR092939A1 (es) Vacuna contra cooperia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)